Zhi Tong Cai Jing·2025-09-18 10:56Core Insights - Novo Nordisk's stock price experienced its largest single-day increase in a month due to the superior performance of its diabetes drug Ozempic compared to Eli Lilly's older drug Trulicity in a real-world study involving U.S. patients [1] - The study presented at the European Association for the Study of Diabetes (EASD) conference indicated that Medicare patients using Ozempic had a 23% lower risk of heart attack, stroke, or death compared to those using Trulicity, tracking nearly 60,000 diabetes and heart disease patients [1] - Both Ozempic and Trulicity belong to the GLP-1 class of drugs, which have transformed obesity treatment, with Novo Nordisk emphasizing the effectiveness of certain drugs in preventing heart disease as a competitive strategy against Eli Lilly [1] - Eli Lilly continues to gain market share with its new drugs Mounjaro and Zepbound [1] - Novo Nordisk's stock rose by 6.5% in Copenhagen following the announcement [1] Additional Insights - A head-to-head study presented at the conference showed that Mounjaro had similar effects to Trulicity in reducing the risk of heart attack, stroke, and death; however, the two studies are not directly comparable due to differences in study design [1]